# Biogen Inc. said it will continue development of its experimental Alzheimer's drug.

*biotech · news · 2026-05-14 · The Boston Globe*

## Key points

- Biogen's diranersen targets tau protein buildup inside neurons using antisense oligonucleotide technology.
- Although the phase II trial missed its primary goal, Biogen saw slower disease progression at all dose levels.
- Patients receiving the lowest dose of diranersen experienced the greatest cognitive benefit in the study.
- Biogen will advance diranersen to a late-stage trial, potentially combining it with amyloid-targeting drugs.

**Companies:** Biogen Inc., Ionis Pharmaceuticals Inc., Eli Lilly & Co.
**Countries:** United States, Japan

[Read the full story on The Boston Globe](https://www.bostonglobe.com/2026/05/14/business/biogen-alzheimers-drug/)

---

Canonical: https://newsio.io/n/a8c056d6-f044-4043-916f-6e1adfa483d8/biogen-inc-said-it-will-continue-development-of-its-experimental-alzheimers-drug
Summarized by Newsio from The Boston Globe. https://newsio.io/how-it-works